http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yoo Bo-Im,Ahan Kwang Bok,Kang Min Hee,Kwon Oh-Seung,Hong Young-Soo,Lee Jung Joon,Lee Hong Sub,Ryu Jung Su,Kim Tae Yong,Moon Dong-Cheul,Song Sukgil,Chung Youn Bok The Pharmaceutical Society of Korea 2005 Archives of Pharmacal Research Vol.28 No.4
We investigated the pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after intravenous (i.v.) bolus administration at a multiple dose every 24 h for 5 days in rats. To analyze ID-6105 levels in biological samples, we used an HPLC-based method which was validated in a pharmacokinetic study by suitable criteria. The concentrations of ID-6105 after the multiple administration for 5 days were not significantly different from the results after the single administration. The $t_{1/2\alpha}, t_{l/2\beta}, V_{dss}, and CL_{t}$ after the multiple administration were not significantly different from the values after the single administration. Moreover, the concentrations of ID-6105 1 min at day 1-5 after i.v. bolus multiple administration did not show the significant difference. Of the various tissues, ID-6105 mainly distributed to the kidney, lung, spleen, adrenal gland, and liver after i.v. bolus multiple administration. ID-6105 concentrations in the kidney or lung 2 h after i.v. bolus administration were comparable to the plasma concentration shortly after i.v. bolus administration. However, the ID-6105 concentrations in various tissues 48 h after i.v. bolus administration decreased to low levels. ID-6105 was excreted largely in the bile after i.v. bolus multiple administration at the dose of 3 mg/kg. The amounts of ID-6105 found in the bile by 12 h or in the urine by 48 h after the administration were calculated to be $14.1\% or 4.55\%$ of the initial dose, respectively, indicating that ID-6105 is mostly excreted in the bile. In conclusion, ID-6105 was rapidly cleared from the blood and transferred to tissues, suggesting that ID-6105 might not be accumulated in the blood following i.v. bolus multiple dosages of 3 mg/kg every 24 h for 5 days. By 48 h after i.v. bolus administration, ID-6105 concentrations in various tissues had decreased to very low levels. The majority of ID-6105 appears to be excreted in the bile.
Yoo, Bo-Im,Ahan, Kwang Bok,Kang, Min Hee,Moon, Dong-Cheul,Kwon, Oh-Seung,Lee, Hong Sub,Ryu, Jung Su,Kim, Tae Yong,Song, Sukgil,Chung, Youn Bok Pharmaceutical Society of Japan 2005 Biological & pharmaceutical bulletin Vol.28 No.4
<P>We investigated the pharmacokinetic characteristics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after intravenous (i.v.) bolus administration in rats and beagle dogs. We developed an HPLC-based method to analyze ID-6105 levels in plasma, bile, urine, feces, and tissue homogenates and validated the method in a pharmacokinetic study. The plasma concentration of ID-6105 decreased to below the quantifiable limit (0.02 μg/ml) at 4 and 8 h after i.v. administration in rats at doses of 2 and 10 mg/kg, respectively (<I>t</I><SUB>1/2,α</SUB> and <I>t</I><SUB>1/2,β</SUB> of 0.78 and 17.8 min at a dose of 2 mg/kg, 0.91 and 176 min at a dose of 10 mg/kg, respectively). The <I>AUC</I> increased with nonlinear pharmacokinetics following the dosage increase from 2 to 10 mg/kg in rats, while the pharmacokinetics were not significantly altered in beagle dogs following a dosage increase from 0.5 to 2.5 mg/kg. Of the various tissues tested, ID-6105 was mainly distributed in the lung, spleen, kidney, adrenal gland, and liver after i.v. bolus administration. ID-6105 levels in the lung or kidney 2 h after i.v. bolus administration were comparable to the initial plasma concentration. However, the ID-6105 concentrations in various tissues 48 h after i.v. bolus administration became too small to measure. The cumulative amounts of ID-6105 found in the bile 48 h after the administration of 2 and 10 mg/kg were calculated to be 26.7 and 18.5% of the initial dose, respectively. The corresponding values in the urine 72 h after i.v. administration were 4.33 and 3.07% of the initial dose, suggesting that ID-6105 is mostly excreted in the bile. In conclusion, our observations indicate that ID-6105 was rapidly cleared from the blood and transferred to tissues such as the lung, spleen, kidney, and liver 2 h after i.v. bolus administration. Moreover, the majority of ID-6105 appears to be excreted in the bile by 24 h after i.v. bolus administration.</P>
Thrombospondin-1 첫 번째 type I repeat 펩티드의 신혈관형성 억제작용
유보임(Bo-Im Yoo),정구보(Goo-Bo Jeong) 대한체질인류학회 2015 대한체질인류학회지 Vol.28 No.4
신혈관형성 (angiogenesis)은 척추동물의 발생과정 또는 질병 시에 수반되는 중요한 생물학적 현상이다. 혈관형성 억제물질의 하나로 알려진 Thrombospondin-1 (TSP-1)은 CSVTCG 아미노산 서열을 포함하는 두 번째와 세 번째 type I repeat 부분이 혈관내피세포의 이동을 억제함으로써 혈관형성을 차단하는 것으로 알려져 있으나 CSVTCG 서열과 다른 서열을 갖는 첫 번째 type I repeat 부분의 역할은 잘 알려져 있지 않았다. 따라서 본 연구에서는 아미노산 서열의 차이를 나타내는 사람과 소 TSP-1의 첫 번째 type I repeat 부분 (TSR-1)이 신혈관형성 억제능력에 있어서 어떠한 차이를 나타내는지 규명하였다. 이를 위해 TSR-1 펩티드 또는 PBS를 섞은 Matrigel에 bFGF를 첨가하여 생쥐복부피하에 주사함으로써 신혈관형성을 유도하였고 일주일 후에 헤모글로빈 양, 혈관의 개수, Matrigel의 색수치 등을 비교하여 신혈관형성 억제능력을 비교하였다. 또한 계란의 융모막 시험법을 통해서도 혈관형성을 억제하는지 확인하였다. 시험관내분석을 위해서는 TSR-1 펩티드를 배양 중인 HUVEC 세포에 처리하여 세포의 증식, 이동 및 맥관형성능력 등을 비교하였다. TSR-1 펩티드의 세포사멸효과는 유세포분석법으로 비교하였다. 실험 결과 소와 사람의 TSR-1 펩티드는 in vivo Matrigel assay와 CAM assay에서 신혈관형성을 억제하였으며, 소의 TSR-1 펩티드가 사람의 TSR-1 또는 대조군 펩티드 (CSVTCG)에 비해 강한 억제효과를 나타내었다. 그리고 소와 사람 TSR-1 펩티드 및 CSVTCG 펩티드는 모두 HUVEC 세포의 증식은 억제하지 못했지만 세포이동 및 세포사멸을 조절함으로써 신혈관형성을 억제하였다. 이상의 실험 결과를 통해 사람과 소의 TSR-1 펩티드는 아미노산 서열은 다르지만 CSVTCG 서열이 아니더라도 유사한 펩티드로서 신혈관형성을 억제하는 능력을 나타낸다는 사실을 확인할 수 있었다. Angiogenesis is the fundamental biological phenomenon in the development of vertebrates and various pathophysiological process such as cancer, inflammation and wound healing. Thrombospondin-1 is a well-known anti-angiogenic molecule which is distributed in the extracellular matrix of various tissues. The second and third type I repeats of human TSP-1 have inhibitory effects on endothelial cell migration and induce angiogenesis inhibition. However the role of the first type I repeat was not elucidated. In addition, the first type I repeat of bovine TSP-1 has CSVTCG amino acid sequence which is known to have anti-angiogenic activity. In the present study, we compared the inhibition of angiogenesis to investigate the role of the first type I repeat of the human and bovine TSP-1. Matrigel was mixed with or without TSR-1 peptides and then injected into C57BL/6J mice. We compared angiogenesis inhibition activity by hemoglobin assay, microvessel density and optical density value after 7 days. Furthermore, inhibition of angiogenesis was confirmed on CAM assay by TSR-1 peptides. For in vitro angiogenesis assay, TSR-1 peptides were treated on the proliferation, migration, and tube formation assay of HUVEC. Apoptosis effect of TSR-1 peptides was confirmed by apoptosis assay kit and flow cytometry. Bovine and human TSR-1 peptides blocked neovascularization in in vivo Matrigel plug assay and CAM assay at 10 μM. Bovine TSR-1 peptides have shown stronger angiogenesis inhibition in bFGF-induced angiogenesis than human TSR-1 and CSVTCG peptides. However, all of TSR-1 peptides inhibit migration and tube formation of HUVEC in in vitro. Furthermore, these peptides also induced apoptosis of HUVEC. These results suggest that TSR-1 peptides of bovine and human TSP-1 have angiogenesis inhibition activity.
유영태,김재열,노경보,양동조,오용석,임기건,김지환 한국공작기계학회 2003 한국생산제조학회지 Vol.12 No.6
With the increased use of lasers in industrial welding applications, techniques for monitoring and controlling these processes become increasingly important. It is very important that we understand the dynamic behaviors of the laser induced plume in welding because the laser induced plume has considerable effects on welding efficiency and the quality of materials. As the plume fluctuation was associated with keyhole instability, unstable vapor plume indicated the process was unstable and would result in poor welds. An Infrared Themal-vision Camera can be utilized compensate for incurracies encountered in real-time monitoring during laser welding. We have results that instabilities of plume are closely dated with hot cracking and defect of laser welding.
Kim, Bo Eun,Koh, Kyung-Nam,Suh, Jin Kyung,Im, Ho Joon,Song, Joon Sup,Lee, Ji Won,Kang, Hyoung Jin,Park, Kyung Duck,Shin, Hee Young,Choi, Hyoung Soo,Lee, Soo Hyun,Yoo, Keon Hee,Sung, Ki Woong,Koo, Hong by Lippincott Williams Wilkins. 2014 Journal of pediatric hematology/oncology Vol.36 No.2
A nationwide survey was conducted to clarify the clinical features and outcomes of Korean children with Langerhans cell histiocytosis (LCH). Korea Histiocytosis Working Party analyzed the data of 603 patients who were diagnosed with LCH between 1986 and 2010 from 28 institutions in Korea. Median age at diagnosis was 65 months (range, 0 to 276 mo). Bone was the most frequently affected organ (79.6%) followed by skin (19.2%). Initially, 419 patients (69.5%) had single-system involvement (SS), 85 (14.1%) with multisystem (MS) disease without risk organ involvement (MS-RO), and 99 (16.4%) multisystem disease with risk organ involvement (MS-RO). The 5-year overall survival (OS) rates in the SS, MS-RO, and MS-RO groups were 99.8%, 98.4%, and 77.0%, respectively (P<0.001), and the 5-year reactivation rates were 17.9%, 33.5%, and 34.3%, respectively (P<0.001). The OS rate was lower in patients with RO involvement (P=0.025) and lack of response to initial treatment (P=0.001). MS involvement (P=0.036) was an independent risk factor for reactivation. Permanent consequences were documented in 99 patients (16.4%). Reactivation of disease, MS involvement, and age at diagnosis ≤2 years were associated with higher incidence of permanent consequences. This study emphasized that further efforts are required to improve survival of MS-RO patients and reduce reactivation in younger patients with MS involvement.